Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetWages, Salaries and Other
Ratios

UroGen Pharma (URGN) Leases (2019 - 2025)

UroGen Pharma's Leases history spans 7 years, with the latest figure at $5.4 million for Q4 2025.

  • For Q4 2025, Leases rose 533.22% year-over-year to $5.4 million; the TTM value through Dec 2025 reached $5.4 million, up 533.22%, while the annual FY2025 figure was $5.4 million, 533.22% up from the prior year.
  • Leases reached $5.4 million in Q4 2025 per URGN's latest filing, roughly flat from $5.4 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $5.4 million in Q3 2025 to a low of $849000.0 in Q4 2024.
  • Average Leases over 5 years is $2.3 million, with a median of $1.8 million recorded in 2023.
  • Peak YoY movement for Leases: plummeted 65.63% in 2021, then soared 533.22% in 2025.
  • A 5-year view of Leases shows it stood at $1.2 million in 2021, then soared by 107.8% to $2.5 million in 2022, then tumbled by 31.85% to $1.7 million in 2023, then plummeted by 49.19% to $849000.0 in 2024, then skyrocketed by 533.22% to $5.4 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Leases are $5.4 million (Q4 2025), $5.4 million (Q3 2025), and $4.3 million (Q2 2025).